| 1 |
Design of α-helical antimicrobial peptides with a high selectivity index.
Juretić, Davor, Simunić, Juraj,
pp. 1-11
|
2019 |
418
|
| 9 |
Computational re-design of protein structures to improve solubility.
Navarro, Susanna, Ventura, Salvador,
Vol. 14 pp. 1077-1088
|
2019 |
359
|
| 11 |
The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
Reimão, Juliana Q, Pita Pedro, Débora P, Coelho, Adriano C,
pp. 1-12
|
2020 |
356
|
| 2 |
An overview of late-stage functionalization in today's drug discovery.
Moir, Michael, Danon, Jonathan J, Reekie, Tristan A, Kassiou, Michael,
pp. 1-13
|
2019 |
354
|
| 3 |
An outlook on using serial femtosecond crystallography in drug discovery
Mishin, A.
Vol. 14 pp. 933-945
|
2019 |
319
|
| 10 |
Future challenges with DNA-encoded chemical libraries in the drug discovery domain.
Zhao, Guixian, Huang, Yiran, Zhou, Yu, Li, Yizhou, Li, Xiaoyu,
Vol. 14 pp. 735-753
|
2019 |
294
|
| 4 |
Cell death assays for neurodegenerative disease drug discovery
Linsley, J.
Vol. 14 pp. 901-913
|
2019 |
282
|
| 7 |
How can molecular micro-CT imaging revolutionize drug discovery?
Shakeri-Zadeh, A.
Vol. 14 pp. 849-853
|
2019 |
273
|
| 5 |
Chikungunya virus drug discovery: still a long way to go?
Pérez-Pérez, M.
Vol. 14 pp. 855-866
|
2019 |
258
|
| 8 |
Challenges to drug discovery for celiac disease and approaches to overcome them
Vaquero, L.
Vol. 14 pp. 957-968
|
2019 |
258
|
| 23 |
influence of entrepreneurial orientation on bussiness performance: the software firms of yucatan, méxico case
, Anel Flores Novelo, Fernando Ojeda-Villagómez, Hyun Sook Lee Kim, Eduardo Ramírez Cedillo
Vol. 5 pp. 25-34
|
2017 |
215
|
| 19 |
the relationship of csr and the business profit: can the most responsible companies be more profitable?
, Antonio Miguel Gil Salmerón
Vol. 5 pp. 60-71
|
2016 |
211
|
| 13 |
Animal models of hyperfunctioning parathyroid diseases for drug development
Imanishi, Yasuo, Inaba, Masaaki, Kawata, Takehisa, Nishizawa, Yoshiki,
Vol. 4 pp. 727-740
|
2009 |
210
|
| 6 |
Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches
González, J.
Vol. 14 pp. 879-891
|
2019 |
175
|
| 15 |
Successes, failures, and future prospects of prodrugs and their clinical impact
Najjar, Anas, Karaman, Rafik,
Vol. 14 pp. 199-220
|
2019 |
168
|
| 12 |
Modeling heart failure in animal models for novel drug discovery and development
Janssen, Paul M. L., Elnakish, Mohammad T.,
Vol. 14 pp. 355-363
|
2019 |
168
|
| 24 |
intrapreneur organizational culture and gender manager: an empirical study on smes
, Monica García Solarte, Domingo García Perez de Lema, Antonia Madrid Guijarro
Vol. 4 pp. 8-18
|
2015 |
152
|
| 18 |
cluster electrónico para el desarrollo competitivo de mipymes a partir de acciones de inteligencia competitiva
, Heber González Gutiérrez
Vol. 1 pp. 75-90
|
2012 |
139
|
| 14 |
Learning from our failures in blood–brain permeability: what can be done for new drug discovery?
Martel, Sylvain,
Vol. 10 pp. 207-211
|
2015 |
138
|
| 16 |
The successes and failures of HIV drug discovery
Hashimoto, Chie, Tanaka, Tomohiro, Narumi, Tetsuo, Nomura, Wataru, Tamamura, Hirokazu,
Vol. 6 pp. 1067-1090
|
2011 |
131
|